Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBS2418 in advanced solid tumors
NCT05270213Phase 1Recruiting
- Sponsor
- Riboscience LLC
- Start
- Jul 2022
- Primary completion
- Apr 2027
- Modality
- Prophylactic Vaccines, Small Molecules, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of rbs2418 in solid tumor (advanced stage) (3 arms), sponsored by Riboscience LLC. Primary endpoints: Dose Limiting Toxicities at 21 days, Peak Plasma Concentration at 5 days and 4 more. Started Jul 2022; status: recruiting.
02
Drugs
rbs2418
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05270213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05270213.